HuMax-IL8: Phase Ib started

Cormorant began the open-label, dose-escalation, U.S. Phase Ib trial to evaluate IV HuMax-IL8 every 2 weeks in about 44 patients. Cormorant has exclusive, worldwide rights to the product from Genmab (...